Wedbush Remains Neutral on BioMarin Pharma (BMRN) - PT to $104

September 7, 2016 9:04 AM EDT
Get Alerts BMRN Hot Sheet
Price: $86.31 -0.98%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade BMRN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Wedbush maintained a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and cut the price target to $104.00 (from $108.00), as the PDUFA date for Brineura for CLN2 disease was delayed to April 27, 2017.

Analyst Liana Moussatos commented, "We consider the PDUFA extension and plans for an advisory committee for Brineura treatment of CLN2 disease as a minor negative. Due to the high unmet need, we believe Brineura is likely to receive first-pass approval."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $95.59 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Liana Moussatos, PDUFA

Add Your Comment